复合炎症指标对冠脉支架内再狭窄预测的研究进展
Research Progress on the Prediction of Coronary In-Stent Restenosis Using Composite Inflammatory Indices
DOI: 10.12677/acm.2025.15113227, PDF,   
作者: 李 诗, 刘晓燃, 袁忠明*：重庆医科大学附属第二医院老年医学科，重庆
关键词: 复合炎症指标；支架内再狭窄；冠心病；Composite Inflammatory Indices； In-Stent Restenosis； Coronary Heart Disease
摘要: 冠心病(CHD)属于慢性炎症性病变，临床上常采用经皮冠状动脉介入治疗(PCI)作为血运重建的关键手段。然而，该治疗术后可能出现的支架内再狭窄(ISR)，是影响治疗效果的主要并发症之一。随着相关机制研究的不断深入，炎症反应被证实与ISR的发生发展关系密切。复合炎症指标是基于单一炎症指标衍生而来，因其能够更全面、综合地反映机体炎症状态，所以在评估疾病进展、识别高危人群以及改善长期预后方面具有重要意义，是预测ISR风险的可靠生物标志物，有望为临床预后判断与个体化治疗提供指导。本文就多种复合炎症指标作为冠脉ISR预测因子的研究进行综述。
Abstract: Coronary heart disease (CHD) is characterized as a chronic inflammatory process, and percutaneous coronary intervention (PCI) is widely employed as a pivotal revascularization strategy. However, in-stent restenosis (ISR), a common complication following PCI, significantly impacts long-term treatment efficacy. Growing mechanistic evidence has established a close association between inflammatory responses and the pathogenesis of ISR. Derived from individual inflammatory markers, composite inflammatory indices provide a more comprehensive and integrated assessment of systemic inflammation. These indices are valuable for evaluating disease progression, identifying high-risk patients, and improving long-term outcomes, serving as reliable biomarkers for predicting ISR risk. They also offer potential guidance for prognostic assessment and personalized therapeutic approaches. This review summarizes current research on various composite inflammatory indices as predictors of coronary ISR.
文章引用：李诗, 刘晓燃, 袁忠明. 复合炎症指标对冠脉支架内再狭窄预测的研究进展[J]. 临床医学进展, 2025, 15(11): 1333-1341. https://doi.org/10.12677/acm.2025.15113227

参考文献

[1] 刘明波, 何新叶, 杨晓红, 等. 《中国心血管健康与疾病报告2024》要点解读[J]. 临床心血管病杂志, 2025, 41(7): 492-511.
[2] Protty, M.B., Dissanayake, T., Jeffery, D., Hailan, A. and Choudhury, A. (2023) Stent Failure: The Diagnosis and Management of Intracoronary Stent Restenosis. Expert Review of Cardiovascular Therapy, 21, 501-506. [Google Scholar] [CrossRef] [PubMed]
[3] Neumann, F., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A.P., Benedetto, U., et al. (2018) 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 40, 87-165. [Google Scholar] [CrossRef] [PubMed]
[4] Mehran, R., Dangas, G., Abizaid, A.S., Mintz, G.S., Lansky, A.J., Satler, L.F., et al. (1999) Angiographic Patterns of In-Stent Restenosis: Classification and Implications for Long-Term Outcome. Circulation, 100, 1872-1878. [Google Scholar] [CrossRef] [PubMed]
[5] Gupta, A., Maitas, O. and Patel, R.A.G. (2025) Recurrent Drug Eluting Stent, In-Stent Restenosis (DES-ISR): Epidemiology, Pathophysiology & Treatment. Progress in Cardiovascular Diseases, 88, 68-74. [Google Scholar] [CrossRef] [PubMed]
[6] Li, J., Nie, S., Zhang, C., Gao, Z., Zheng, X. and Guo, Y. (2007) Is Inflammation a Contributor for Coronary Stent Restenosis? Medical Hypotheses, 68, 945-951. [Google Scholar] [CrossRef] [PubMed]
[7] Silvestre-Roig, C., Braster, Q., Ortega-Gomez, A. and Soehnlein, O. (2020) Neutrophils as Regulators of Cardiovascular Inflammation. Nature Reviews Cardiology, 17, 327-340. [Google Scholar] [CrossRef] [PubMed]
[8] Bajeu, I., Niculescu, A., Scafa-Udriște, A. and Andronescu, E. (2024) Intrastent Restenosis: A Comprehensive Review. International Journal of Molecular Sciences, 25, Article 1715. [Google Scholar] [CrossRef] [PubMed]
[9] Haybar, H., Pezeshki, S.M.S. and Saki, N. (2021) Platelets in In-Stent Restenosis: From Fundamental Role to Possible Prognostic Application. Current Cardiology Reviews, 16, 285-291. [Google Scholar] [CrossRef] [PubMed]
[10] Komiyama, H. (2015) Neoatherosclerosis: Coronary Stents Seal Atherosclerotic Lesions but Result in Making a New Problem of Atherosclerosis. World Journal of Cardiology, 7, 776-783. [Google Scholar] [CrossRef] [PubMed]
[11] Yousuf, O., Mohanty, B.D., Martin, S.S., Joshi, P.H., Blaha, M.J., Nasir, K., et al. (2013) High-Sensitivity C-Reactive Protein and Cardiovascular Disease: A Resolute Belief or an Elusive Link? Journal of the American College of Cardiology, 62, 397-408. [Google Scholar] [CrossRef] [PubMed]
[12] Spitz, C., Winkels, H., Bürger, C., Weber, C., Lutgens, E., Hansson, G.K., et al. (2015) Regulatory T Cells in Atherosclerosis: Critical Immune Regulatory Function and Therapeutic Potential. Cellular and Molecular Life Sciences, 73, 901-922. [Google Scholar] [CrossRef] [PubMed]
[13] Linton, M.F., Yancey, P.G., Tao, H. and Davies, S.S. (2023) HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy. Circulation Research, 132, 1521-1545. [Google Scholar] [CrossRef] [PubMed]
[14] Arques, S. (2020) Serum Albumin and Cardiovascular Disease: State-Of-The-Art Review. Annales de Cardiologie et d’Angéiologie, 69, 192-200. [Google Scholar] [CrossRef] [PubMed]
[15] Shetty, S. and Subramanian, M. (2025) Neutrophil Extracellular Traps (nets) as Drivers of Atherosclerosis: Pathogenic Mechanisms and Therapeutic Opportunities. Pharmacology & Therapeutics, 274, Article ID: 108917. [Google Scholar] [CrossRef] [PubMed]
[16] Nijm, J. and Jonasson, L. (2009) Inflammation and Cortisol Response in Coronary Artery Disease. Annals of Medicine, 41, 224-233. [Google Scholar] [CrossRef] [PubMed]
[17] Arbel, Y., Finkelstein, A., Halkin, A., Birati, E.Y., Revivo, M., Zuzut, M., et al. (2012) Neutrophil/Lymphocyte Ratio Is Related to the Severity of Coronary Artery Disease and Clinical Outcome in Patients Undergoing Angiography. Atherosclerosis, 225, 456-460. [Google Scholar] [CrossRef] [PubMed]
[18] Siahaan, P.P., Widiarti, W., Saputra, P.B.T., Putra, R.M. and D’Oria, M. (2025) Neutrophil-to-Lymphocyte Ratio as a Potential Biomarker in Predicting In-Stent Restenosis: A Systematic Review and Meta-Analysis. PLOS One, 20, e0322461. [Google Scholar] [CrossRef] [PubMed]
[19] Turak, O., Ozcan, F., Isleyen, A., Tok, D., Sokmen, E., Buyukkaya, E., et al. (2012) Usefulness of the Neutrophil-To-Lymphocyte Ratio to Predict Bare-Metal Stent Restenosis. The American Journal of Cardiology, 110, 1405-1410. [Google Scholar] [CrossRef] [PubMed]
[20] Balli, M., Taşolar, H., Çetin, M., Tekin, K., Çağliyan Ç.E., Türkmen, S., et al. (2015) Use of the Neutrophil to Lymphocyte Ratio for Prediction of In-Stent Restenosis in Bifurcation Lesions. European Review for Medical and Pharmacological Sciences, 19, 1866-1873.
[21] Gabbasov, Z., Kozlov, S., Melnikov, I., Byazrova, S., Saburova, O., Prokofieva, L., et al. (2018) Novel Biomarkers for Coronary Restenosis Occurrence after Drug-Eluting Stent Implantation in Patients with Diabetes Having Stable Coronary Artery Disease. Clinical and Applied Thrombosis/Hemostasis, 24, 1308-1314. [Google Scholar] [CrossRef] [PubMed]
[22] May, A.E., Seizer, P. and Gawaz, M. (2008) Platelets: Inflammatory Firebugs of Vascular Walls. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, s5-s10. [Google Scholar] [CrossRef] [PubMed]
[23] Budzianowski, J., Pieszko, K., Burchardt, P., Rzeźniczak, J. and Hiczkiewicz, J. (2017) The Role of Hematological Indices in Patients with Acute Coronary Syndrome. Disease Markers, 2017, Article ID: 3041565. [Google Scholar] [CrossRef] [PubMed]
[24] Kaplan, A., Altara, R., Eid, A., Booz, G.W. and Zouein, F.A. (2016) Update on the Protective Role of Regulatory T Cells in Myocardial Infarction: A Promising Therapy to Repair the Heart. Journal of Cardiovascular Pharmacology, 68, 401-413. [Google Scholar] [CrossRef] [PubMed]
[25] Tudurachi, B., Anghel, L., Tudurachi, A., Sascău, R.A. and Stătescu, C. (2023) Assessment of Inflammatory Hematological Ratios (NLR, PLR, MLR, LMR and Monocyte/HDL-Cholesterol Ratio) in Acute Myocardial Infarction and Particularities in Young Patients. International Journal of Molecular Sciences, 24, Article 14378. [Google Scholar] [CrossRef] [PubMed]
[26] Wang, H., Zulikaier, T., Yumaierjiang, B., Lyu, S. and He, P. (2025) Platelet-to-Lymphocyte Ratio Efficiency in Predicting Major Adverse Cardiovascular Events after Percutaneous Coronary Intervention in Acute Coronary Syndromes: A Meta-Analysis. Reviews in Cardiovascular Medicine, 26, Article 27942. [Google Scholar] [CrossRef] [PubMed]
[27] Yılmaz, S., Sen, F., Ünal, S., Yayla, C., Özeke, Ö., Aras, D., et al. (2014) Usefulness of the Platelet-To-Lymphocyte Ratio in Predicting Bare-Metal Stent Restenosis. Scandinavian Cardiovascular Journal, 49, 39-44. [Google Scholar] [CrossRef] [PubMed]
[28] Li, C., Shen, Y., Xu, R., Dai, Y., Chang, S., Lu, H., et al. (2018) Evaluation of Preprocedural Laboratory Parameters as Predictors of Drug-Eluting Stent Restenosis in Coronary Chronic Total Occlusion Lesions. Angiology, 70, 272-278. [Google Scholar] [CrossRef] [PubMed]
[29] Ma, L., Xu, H., Li, H. and Liu, D. (2025) Predictive Utility of PLR and Platelet-To-LDL Ratio for In-Stent Restenosis Following Carotid Artery Stenting. Vascular Health and Risk Management, 21, 671-684. [Google Scholar] [CrossRef] 
[30] Murat, S.N., Yarlioglues, M., Celik, I.E., Kurtul, A., Duran, M., Kilic, A., et al. (2016) The Relationship between Lymphocyte-To-Monocyte Ratio and Bare-Metal Stent In-Stent Restenosis in Patients with Stable Coronary Artery Disease. Clinical and Applied Thrombosis/Hemostasis, 23, 235-240. [Google Scholar] [CrossRef] [PubMed]
[31] Hou, L., Su, K., He, T., Zhao, J. and Li, Y. (2024) Using XGBoost for Predicting In-Stent Restenosis Post-Des Implantation: Role of Lymphocyte-To-Monocyte Ratio and Residual Cholesterol. International Journal of General Medicine, 17, 3443-3452. [Google Scholar] [CrossRef] [PubMed]
[32] Quan, X., Wang, R., Zhang, Q., Zhang, C. and Sun, L. (2020) The Predictive Value of Lymphocyte-To-Monocyte Ratio in the Prognosis of Acute Coronary Syndrome Patients: A Systematic Review and Meta-Analysis. BMC Cardiovascular Disorders, 20, Article No. 338. [Google Scholar] [CrossRef] [PubMed]
[33] Gong, S., Gao, X., Xu, F., Shang, Z., Li, S., Chen, W., et al. (2018) Association of Lymphocyte to Monocyte Ratio with Severity of Coronary Artery Disease. Medicine, 97, e12813. [Google Scholar] [CrossRef] [PubMed]
[34] Hu, B., Yang, X., Xu, Y., Sun, Y., Sun, C., Guo, W., et al. (2014) Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research, 20, 6212-6222. [Google Scholar] [CrossRef] [PubMed]
[35] Ye, Z., Hu, T., Wang, J., Xiao, R., Liao, X., Liu, M., et al. (2022) Systemic Immune-Inflammation Index as a Potential Biomarker of Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 9, Article 933913. [Google Scholar] [CrossRef] [PubMed]
[36] Liu, Y., Ye, T., Chen, L., Jin, T., Sheng, Y., Wu, G., et al. (2021) Systemic Immune-Inflammation Index Predicts the Severity of Coronary Stenosis in Patients with Coronary Heart Disease. Coronary Artery Disease, 32, 715-720. [Google Scholar] [CrossRef] [PubMed]
[37] Xie, F., Yu, Z., Xiong, Y., Wu, Z. and Wu, Y. (2024) Systemic Immune-Inflammation Index and In-Stent Restenosis in Patients with Acute Coronary Syndrome: A Single-Center Retrospective Study. European Journal of Medical Research, 29, Article No. 145. [Google Scholar] [CrossRef] [PubMed]
[38] Ösken, A., Polat, F., Çakir, B., Zengin, A., Çalik, A.N., Ünal Dayi, Ş., et al. (2024) Systemic Immune Inflammation Index and Its Implication on In-Stent Restenosis among Patients with Acute Coronary Syndrome. Coronary Artery Disease, 35, 209-214. [Google Scholar] [CrossRef] [PubMed]
[39] Deng, X., Deng, Q., Zhang, Q. and Hou, J. (2025) Association of Systemic Immune-Inflammatory Index with In-Stent Restenosis in Patients with and without Diabetes Mellitus. Frontiers in Cardiovascular Medicine, 12, Article 1419314. [Google Scholar] [CrossRef] [PubMed]
[40] Xu, P., Cao, Y., Ren, R., Zhang, S., Zhang, C., Hao, P., et al. (2024) Usefulness of the Systemic Inflammation Response Index and the Systemic Immune Inflammation Index in Predicting Restenosis after Stent Implantation. Journal of Inflammation Research, 17, 4941-4955. [Google Scholar] [CrossRef] [PubMed]
[41] Hausenloy, D.J. and Yellon, D.M. (2008) Targeting Residual Cardiovascular Risk: Raising High-Density Lipoprotein Cholesterol Levels. Heart, 94, 706-714. [Google Scholar] [CrossRef] [PubMed]
[42] McLaren, J.E., Michael, D.R., Ashlin, T.G. and Ramji, D.P. (2011) Cytokines, Macrophage Lipid Metabolism and Foam Cells: Implications for Cardiovascular Disease Therapy. Progress in Lipid Research, 50, 331-347. [Google Scholar] [CrossRef] [PubMed]
[43] Tok, D., Turak, O., Yayla, Ç., Ozcan, F., Tok, D. and Çağlı, K. (2016) Monocyte to HDL Ratio in Prediction of BMS Restenosis in Subjects with Stable and Unstable Angina Pectoris. Biomarkers in Medicine, 10, 853-860. [Google Scholar] [CrossRef] [PubMed]
[44] Ucar, F.M. (2016) A Potential Marker of Bare Metal Stent Restenosis: Monocyte Count-To-HDL Cholesterol Ratio. BMC Cardiovascular Disorders, 16, Article No. 186. [Google Scholar] [CrossRef] [PubMed]
[45] Yilmaz, S., Akboga, M.K., Sen, F., Balcı, K.G., Aras, D., Temizhan, A., et al. (2016) Usefulness of the Monocyte-To-High-Density Lipoprotein Cholesterol Ratio to Predict Bare Metal Stent Restenosis. Biomarkers in Medicine, 10, 959-966. [Google Scholar] [CrossRef] [PubMed]
[46] Nan, J., Meng, S., Hu, H., Jia, R., Chen, C., Peng, J., et al. (2020) The Predictive Value of Monocyte Count to High-Density Lipoprotein Cholesterol Ratio in Restenosis after Drug-Eluting Stent Implantation. International Journal of General Medicine, 13, 1255-1263. [Google Scholar] [CrossRef] [PubMed]
[47] Meng, H., Zhou, X., Li, L., Liu, Y., Liu, Y. and Zhang, Y. (2024) Monocyte to High-Density Lipoprotein Cholesterol Ratio Predicts Restenosis of Drug-Eluting Stents in Patients with Unstable Angina Pectoris. Scientific Reports, 14, Article No. 30175. [Google Scholar] [CrossRef] [PubMed]
[48] Chen, B., Liu, J., Xing, J., Liu, H., Wei, Y., Xue, X., et al. (2022) Analysis of the Correlation between the Ratio of Monocytes to High-Density Lipoprotein Cholesterol and In-Stent Restenosis in Patients with Premature Coronary Heart Disease. Clinical and Applied Thrombosis/Hemostasis, 28, 1-9. [Google Scholar] [CrossRef] [PubMed]
[49] Rong, J., Gu, N., Tian, H., Shen, Y., Deng, C., Chen, P., et al. (2024) Association of the Monocytes to High-Density Lipoprotein Cholesterol Ratio with In-Stent Neoatherosclerosis and Plaque Vulnerability: An Optical Coherence Tomography Study. International Journal of Cardiology, 396, Article ID: 131417. [Google Scholar] [CrossRef] [PubMed]
[50] Salazar, J., Martínez, M.S., Chávez-Castillo, M., Núñez, V., Añez, R., Torres, Y., et al. (2014) C-Reactive Protein: An In-Depth Look into Structure, Function, and Regulation. International Scholarly Research Notices, 2014, Article ID: 653045. [Google Scholar] [CrossRef] [PubMed]
[51] Manolis, A.A., Manolis, T.A., Melita, H., Mikhailidis, D.P. and Manolis, A.S. (2022) Low Serum Albumin: A Neglected Predictor in Patients with Cardiovascular Disease. European Journal of Internal Medicine, 102, 24-39. [Google Scholar] [CrossRef] [PubMed]
[52] Kalyoncuoglu, M. and Durmus, G. (2020) Relationship between C-Reactive Protein-To-Albumin Ratio and the Extent of Coronary Artery Disease in Patients with Non-St-Elevated Myocardial Infarction. Coronary Artery Disease, 31, 130-136. [Google Scholar] [CrossRef] [PubMed]
[53] Aksu, U., Gulcu, O., Aksakal, E., Kalkan, K., Öztürk, M., Korkmaz, A.F., et al. (2019) The Association between CRP/Albumin Ratio and In‐stent Restenosis Development in Patients with St‐segment Elevation Myocardial Infarction. Journal of Clinical Laboratory Analysis, 33, e22848. [Google Scholar] [CrossRef] [PubMed]
[54] Rencuzogullari, I., Karabağ, Y., Çağdaş, M., Karakoyun, S., Seyis, S., Gürsoy, M.O., et al. (2019) Assessment of the Relationship between Preprocedural C-Reactive Protein/Albumin Ratio and Stent Restenosis in Patients with ST-Segment Elevation Myocardial Infarction. Revista Portuguesa de Cardiologia, 38, 269-277. [Google Scholar] [CrossRef] [PubMed]
[55] Durmuş, G., Karataş, M.B., Gökalp, M., Eren, S., Cebeci, A.C., Nural, A., et al. (2024) Increased Serum CRP-Albumin Ratio Is Independently Associated with In-Stent Restenosis after Carotid Artery Stenting. Angiology. [Google Scholar] [CrossRef] [PubMed]

为你推荐